Solomon Moshkevich - 01 Sep 2026 Form 4 Insider Report for Natera, Inc. (NTRA)

Reporting relationship: PRESIDENT, CLINICALDIAGNOSTICS
Issuer ticker: NTRA
Reported as of: 01 Sep 2026
Net transaction value: -$5,917,907
SEC form: 4
Accepted by SEC: 03 Sep 2026, 21:35:05 UTC
Prior SEC filing: 05 Aug 2026
Source filing: View source filing
Reporting owner signature: /s/ Tami Chen, Attorney-in-Fact

Key filing fact

Solomon Moshkevich filed Form 4 for Natera, Inc. (NTRA) on 03 Sep 2026.

Key facts

This page summarizes Solomon Moshkevich's Form 4 filing for Natera, Inc. (NTRA).
4 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 03 Sep 2026, 21:35.

Change

Previous filing in this sequence was filed on 05 Aug 2026.
Current net transaction value: -$5,917,907.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002010019 Primary reporting owner

Moshkevich Solomon

Relationship: PRESIDENT, CLINICALDIAGNOSTICS
Address: C/O NATERA, INC., 13011 MCCALLEN PASS BUILDING A SUITE 100, AUSTIN
Signature: /s/ Tami Chen, Attorney-in-Fact
Signature date: 03 Sep 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

NTRA transaction

Common Stock

Sale

Transaction value: $319,758
Shares: -1,000
Change %: -0.78%
Price: $319.76
Shares after: 128,019
Date: 01 Sep 2026
Ownership: Direct
Footnotes: F1, F2

NTRA transaction

Common Stock

Sale

Transaction value: $449,292
Shares: -1,400
Change %: -1.1%
Price: $320.92
Shares after: 126,619
Date: 01 Sep 2026
Ownership: Direct
Footnotes: F1, F3

NTRA transaction

Common Stock

Sale

Transaction value: $193,144
Shares: -600
Change %: -0.47%
Price: $321.91
Shares after: 126,019
Date: 01 Sep 2026
Ownership: Direct
Footnotes: F1, F4

NTRA transaction

Common Stock

Sale

Transaction value: $4,955,713
Shares: -15,160
Change %: -12%
Price: $326.89
Shares after: 110,859
Date: 02 Sep 2026
Ownership: Direct
Footnotes: F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 5 footnotes

Footnote F1

The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024.

Footnote F2

The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $319.2850 to $320.26 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Footnote F3

The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $320.36 to $321.17 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Footnote F4

The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $321.49 to $322.11 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Footnote F5

The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and was made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on August 25, 2023.